Advanced search
Publication Cover
Expert Opinion on Biological Therapy Volume 20, 2020 - Issue 7
Submit an article Journal homepage
3,449
Views
36
CrossRef citations to date
0
Altmetric
Original Research

One-year effectiveness, retention rate, and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a real-life multicenter study

Maria Sole Chimentia Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, ItalyCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1343-1729View further author information
ORCID Icon,
Giulia Lavinia Fontia Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, ItalyView further author information
,
Paola Conigliaroa Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, ItalyView further author information
,
Flavia Sunzinia Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, ItalyView further author information
,
Rossana Scrivob UOC di Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, ItalyView further author information
,
Luca Navarinic Unit of Allergology, Immunology and Rheumatology, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, ItalyORCID Iconhttps://orcid.org/0000-0001-8537-1510View further author information
ORCID Icon,
Paola Triggianesea Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, ItalyView further author information
,
Giusy Pelusod Istituto di Reumatologia e Scienze Affini, Università Cattolica del Sacro Cuore- Fondazione Policlinico Universitario Agostino Gemelli – IRCCS- Presidio Columbus, Rome, ItalyView further author information
,
Palma Scolierie UOC di Medicina Interna e Reumatologia, Ospedale Nuovo Regina Margherita, Rome, ItalyView further author information
,
Rosalba Caccavalef Dipartimento di Scienze e Biotecnologie Medico-chirurgiche, Sapienza Università di Roma, Polo Pontino, Latina, ItalyView further author information
,
Andrea Picchianti Diamantig Department of Clinical and Molecular Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, ItalyView further author information
,
Erica De Martinoa Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, ItalyView further author information
,
Simonetta Salemig Department of Clinical and Molecular Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, ItalyView further author information
,
Domenico Birrad Istituto di Reumatologia e Scienze Affini, Università Cattolica del Sacro Cuore- Fondazione Policlinico Universitario Agostino Gemelli – IRCCS- Presidio Columbus, Rome, ItalyView further author information
,
Alessio Altobellib UOC di Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, ItalyView further author information
,
Marino Parolif Dipartimento di Scienze e Biotecnologie Medico-chirurgiche, Sapienza Università di Roma, Polo Pontino, Latina, ItalyView further author information
,
Vincenzo Bruzzesee UOC di Medicina Interna e Reumatologia, Ospedale Nuovo Regina Margherita, Rome, ItalyView further author information
,
Bruno Laganàg Department of Clinical and Molecular Medicine, Sant’Andrea University Hospital, Sapienza University of Rome, Rome, ItalyView further author information
,
Elisa Gremesed Istituto di Reumatologia e Scienze Affini, Università Cattolica del Sacro Cuore- Fondazione Policlinico Universitario Agostino Gemelli – IRCCS- Presidio Columbus, Rome, ItalyView further author information
,
Fabrizio Contib UOC di Reumatologia, Dipartimento di Scienze Cliniche Internistiche, Anestesiologiche e Cardiovascolari, Sapienza Università di Roma, Rome, ItalyView further author information
,
Antonella Afeltrac Unit of Allergology, Immunology and Rheumatology, Department of Medicine, Università Campus Bio-Medico di Roma, Rome, ItalyView further author information
&
Roberto Perriconea Rheumatology, Allergology and Clinical Immunology, University of Rome Tor Vergata, Rome, ItalyView further author information
 show all
Pages 813-821 | Received 19 Mar 2020, Accepted 24 Apr 2020, Published online: 13 May 2020

Citations (36)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (5)

Rubén Queiro, Marta Loredo, Ignacio Braña, Estefanía Pardo, Sara Alonso & Mercedes Alperi. (2023) Managing psoriatic arthritis in different clinical scenarios. Expert Review of Clinical Immunology 19:12, pages 1469-1484.
Read now
Flavia Sunzini, Arianna D’Antonio, Mauro Fatica, Paola Triggianese, Paola Conigliaro, Elisabetta Greco, Alberto Bergamini & Maria Sole Chimenti. (2022) What’s new and what’s next for biological and targeted synthetic treatments in psoriatic arthritis?. Expert Opinion on Biological Therapy 22:12, pages 1545-1559.
Read now
Bénédicte Caron, Jean-Yves Jouzeau, Pierre Miossec, Nadine Petitpain, Pierre Gillet, Patrick Netter & Laurent Peyrin-Biroulet. (2022) Gastroenterological safety of IL-17 inhibitors: a systematic literature review. Expert Opinion on Drug Safety 21:2, pages 223-239.
Read now
Fabiola Atzeni, Antonio Carriero, Laura Boccassini & Salvatore D’Angelo. (2021) Anti-IL-17 Agents in the Treatment of Axial Spondyloarthritis. ImmunoTargets and Therapy 10, pages 141-153.
Read now
Maria Sole Chimenti, Arianna D’Antonio, Paola Conigliaro, Sara Ferrigno, Andrea Vendola, Mario Ferraioli, Paola Triggianese, Luisa Costa, Francesco Caso & Roberto Perricone. (2020) An Update for the Clinician on Biologics for the Treatment of Psoriatic Arthritis. Biologics: Targets and Therapy 14, pages 53-75.
Read now

Articles from other publishers (31)

Silvia Scriffignano, Fabio Massimo Perrotta, Paola Conigliaro, Mario Ferraioli, Paola Triggianese, Maria Sole Chimenti & Ennio Lubrano. (2023) Identification of the Minimal Disease Activity Domains Achieved Based on Different Treatments in Psoriatic Arthritis. Rheumatology and Therapy 10:6, pages 1785-1794.
Crossref
Rosario García-Vicuña, Xavier Juanola, Victoria Navarro-Compán, Manuel José Moreno-Ramos, Concepción Castillo-Gallego, Mireia Moreno, Eva Galíndez, María Montoro, Ismael Gómez, Francisco Jose Rebollo-Laserna & Estíbaliz Loza. (2023) Management of Specific Clinical Profiles in Axial Spondyloarthritis: An Expert’s Document Based on a Systematic Literature Review and Extended Delphi Process. Rheumatology and Therapy 10:5, pages 1215-1240.
Crossref
Karl Gaffney, Nicola Gullick, Kirsten MacKay, Yusuf Patel, Raj Sengupta, Tom Sheeran, Louise Hemmings & Paula Pamies. (2023) Real-world evidence for secukinumab in UK patients with psoriatic arthritis or radiographic axial spondyloarthritis: interim 2-year analysis from SERENA. Rheumatology Advances in Practice 7:3.
Crossref
M. Ferrito, G. Cincinelli, M. Manara, R. Di Taranto, E.G. Favalli & R. Caporali. (2023) Retention rate of tumor necrosis factor inhibitors, anti-interleukin 17, and anti-interleukin 12/23 drugs in a single-center cohort of psoriatic arthritis patients. Reumatismo 75:2.
Crossref
Francisca Sivera, Victoria Núñez-Monje, Cristina Campos-Fernández, Isabel Balaguer-Trull, Montserrat Robustillo-Villarino, Marta Aguilar-Zamora, Marta Garijo-Bufort, Juan Miguel López-Gómez, Carolina Peña-González, Isabel de la Morena, Diego Bedoya-Sanchís, Liliya Yankova-Komsalova, Arantxa Conesa-Mateos, Anna Martínez-Cristóbal, Francisco Javier Navarro-Blasco, José Miguel Senabre-Gallego & Juan José Alegre-Sancho. (2023) Real-world experience with secukinumab in the entire axial spondyloarthritis spectrum. Frontiers in Medicine 10.
Crossref
Francesco Molica Colella, Gaetano Zizzo, Vincenzo Parrino, Maria Teresa Filosa, Riccardo Cavaliere, Francesco Fazio, Aldo Biagio Molica Colella & Antonino Mazzone. (2023) Effectiveness and safety of secukinumab in ankylosing spondylitis and psoriatic arthritis: a 52-week real-life study in an Italian cohort. Advances in Rheumatology 63:1.
Crossref
Maxime Dougados, Julien Lucas, Emilie Desfleurs, Pascal Claudepierre, Philippe Goupille, Adeline Ruyssen-Witrand, Alain Saraux, Anne Tournadre, Daniel Wendling & Cédric Lukas. (2023) Factors associated with the retention of secukinumab in patients with axial spondyloarthritis in real-world practice: results from a retrospective study (FORSYA). RMD Open 9:1, pages e002802.
Crossref
Marino Paroli, Rosalba Caccavale, Maria Pia Paroli, Luca Spadea & Daniele Accapezzato. (2023) Janus Kinase Inhibitors: A New Tool for the Treatment of Axial Spondyloarthritis. International Journal of Molecular Sciences 24:2, pages 1027.
Crossref
Oh Chan Kwon & Min-Chan Park. (2023) Drug Retention Rate and Factors Associated with Discontinuation of Interleukin-17 Inhibitors in Patients with Axial Spondyloarthritis. Yonsei Medical Journal 64:12, pages 697.
Crossref
Mauro Fatica, Arianna D’Antonio, Lucia Novelli, Paola Triggianese, Paola Conigliaro, Elisabetta Greco, Alberto Bergamini, Carlo Perricone & Maria Sole Chimenti. (2022) How Has Molecular Biology Enhanced Our Undertaking of axSpA and Its Management. Current Rheumatology Reports 25:1, pages 12-33.
Crossref
Fausto Salaffi, Cesare Siragusano, Alessandra Alciati, Giulia Cassone, Salvatore D’Angelo, Serena Guiducci, Ennio Giulio Favalli, Fabrizio Conti, Elisa Gremese, Florenzo Iannone, Roberto Caporali, Marco Sebastiani, Gian Franco Ferraccioli, Giovanni Lapadula & Fabiola Atzeni. (2022) Axial Spondyloarthritis: Reshape the Future—From the “2022 GISEA International Symposium”. Journal of Clinical Medicine 11:24, pages 7537.
Crossref
Marino Paroli, Rosalba Caccavale, Maria Teresa Fiorillo, Luca Spadea, Stefano Gumina, Vittorio Candela & Maria Pia Paroli. (2022) The Double Game Played by Th17 Cells in Infection: Host Defense and Immunopathology. Pathogens 11:12, pages 1547.
Crossref
Laura Pina Vegas, Léa Hoisnard, Léa Bastard, Emilie Sbidian & Pascal Claudepierre. (2022) Long-term persistence of second-line biologics in psoriatic arthritis patients with prior TNF inhibitor exposure: a nationwide cohort study from the French health insurance database (SNDS). RMD Open 8:2, pages e002681.
Crossref
N. A. Shostak, D. Yu. Andriyashkina, A. S. Dvornikov, N.  M. Babadaev & D. V. Somov. (2022) Interleukin 17A inhibitor secukinumab in the treatment of patients with psoriatic arthritis. The Clinician 16:2, pages 27-39.
Crossref
Uta Kiltz, Petros P. Sfikakis, Karl Gaffney, Andreas Bounas, Nicola Gullick, Eric Lespessailles, Jan Brandt-Juergens, Rasho Rashkov, Barbara Schulz, Effie Pournara & Piotr Jagiello. (2022) Interim 2-Year Analysis from SERENA: A Real-World Study in Patients with Psoriatic Arthritis or Ankylosing Spondylitis Treated with Secukinumab. Rheumatology and Therapy 9:4, pages 1129-1142.
Crossref
Philip J. Mease, Taylor Blachley, Blessing Dube, Robert R. McLean, Nina Kim, Peter Hur & Alexis Ogdie. (2022) Effectiveness of 6-month Use of Secukinumab in Patients With Psoriatic Arthritis in the CorEvitas Psoriatic Arthritis/Spondyloarthritis Registry. The Journal of Rheumatology 49:7, pages 700-706.
Crossref
Brigitte Michelsen, Stylianos Georgiadis, Daniela Di Giuseppe, Anne G. Loft, Michael J. Nissen, Florenzo Iannone, Manuel Pombo‐Suarez, Herman Mann, Ziga Rotar, Kari K. Eklund, Tore K. Kvien, Maria J. Santos, Bjorn Gudbjornsson, Catalin Codreanu, Sema Yilmaz, Johan K. Wallman, Cecilie H. Brahe, Burkhard Möller, Ennio G. Favalli, Carlos Sánchez‐Piedra, Lucie Nekvindova, Matija Tomsic, Nina Trokovic, Eirik K. Kristianslund, Helena Santos, Thorvardur J. Löve, Ruxandra Ionescu, Yavuz Pehlivan, Gareth T. Jones, Irene van der Horst‐Bruinsma, Lykke M. Ørnbjerg, Mikkel Østergaard & Merete L. Hetland. (2022) Real‐World Six‐ and Twelve‐Month Drug Retention, Remission, and Response Rates of Secukinumab in 2,017 Patients With Psoriatic Arthritis in Thirteen European Countries. Arthritis Care & Research 74:7, pages 1205-1218.
Crossref
Laura Pina Vegas, Laetitia Penso, Pascal Claudepierre & Emilie Sbidian. (2022) Long-term Persistence of First-line Biologics for Patients With Psoriasis and Psoriatic Arthritis in the French Health Insurance Database. JAMA Dermatology 158:5, pages 513.
Crossref
María Aparicio, Carlos A. Guillén-Astete, Clementina López-Medina, Carlos Sastre & Fernando J. Rodríguez Martínez. (2021) Evidence for the Use of Secukinumab in Patients with Radiographic and Non-radiographic Axial Spondyloarthritis in the Last 5 Years. Rheumatology and Therapy 9:1, pages 73-94.
Crossref
Alicia García-Dorta, Paola León-Suarez, Sonia Peña, Marta Hernández-Díaz, Carlos Rodríguez-Lozano, Enrique González-Dávila, María Vanesa Hernández-Hernández & Federico Díaz-González. (2022) Association of Gender, Diagnosis, and Obesity With Retention Rate of Secukinumab in Spondyloarthropathies: Results Form a Multicenter Real-World Study. Frontiers in Medicine 8.
Crossref
Roberta Ramonda, Mariagrazia Lorenzin, Maria Sole Chimenti, Salvatore D’Angelo, Antonio Marchesoni, Carlo Salvarani, Ennio Lubrano, Luisa Costa, Ylenia Dal Bosco, Elena Fracassi, Augusta Ortolan, Mario Ferraioli, Antonio Carriero, Elisa Visalli, Riccardo Bixio, Francesca Desiati, Alberto Bergamini, Elisa Pedrollo, Andrea Doria, Rosario Foti & Antonio Carletto. (2022) Effectiveness and safety of secukinumab in axial spondyloarthritis: a 24-month prospective, multicenter real-life study. Therapeutic Advances in Musculoskeletal Disease 14, pages 1759720X2210903.
Crossref
S.P. Déo-Gracias Berry, Camille Dossou, Ali Kashif, Niusha Sharifinejad, Gholamreza Azizi, Haleh Hamedifar, Araz Sabzvari & Zeineb Zian. (2022) The role of IL-17 and anti-IL-17 agents in the immunopathogenesis and management of autoimmune and inflammatory diseases. International Immunopharmacology 102, pages 108402.
Crossref
Maria Sole Chimenti, Paola Conigliaro, Francesco Caso, Luisa Costa, Augusta Ortolan, Paola Triggianese, Marco Tasso, Giulia Lavinia Fonti, Maria Grazia Lorenzin, Roberto Perricone & Roberta Ramonda. (2021) Long-term effectiveness and drug survival of golimumab in patients affected by psoriatic arthritis with cutaneous involvement. Clinical Rheumatology 41:1, pages 75-84.
Crossref
Maria-Sole Chimenti, Rieke Alten, Maria-Antonieta D'Agostino, Elisa Gremese, Uta Kiltz, Ennio Lubrano, Mireia Moreno, Thao Pham, Roberta Ramonda, Francesca-Romana Spinelli, Chiara Perella & Laura Andreoli. (2021) Sex-associated and gender-associated differences in the diagnosis and management of axial spondyloarthritis: addressing the unmet needs of female patients. RMD Open 7:3, pages e001681.
Crossref
Maria Sole Chimenti, Carlo Perricone, Arianna D’Antonio, Mario Ferraioli, Paola Conigliaro, Paola Triggianese, Cinzia Ciccacci, Paola Borgiani & Roberto Perricone. (2021) Genetics, Epigenetics, and Gender Impact in Axial-Spondyloarthritis Susceptibility: An Update on Genetic Polymorphisms and Their Sex Related Associations. Frontiers in Genetics 12.
Crossref
Sara Alonso, Ignacio Villa, Sabela Fernández, José L. Martín, Lilyan Charca, Marina Pino, Leyre Riancho, Isla Morante, Monserrat Santos, Anahy Brandy, Elena Aurrecoechea, Loreto Carmona & Rubén Queiro. (2021) Multicenter Study of Secukinumab Survival and Safety in Spondyloarthritis and Psoriatic Arthritis: SEcukinumab in Cantabria and ASTURias Study. Frontiers in Medicine 8.
Crossref
E. E. Gubar, Yu. L. Korsakova, E. Yu. Loginova, A. V. Smirnov, S. I. Glukhova & T. V. Korotaeva. (2021) Effect of tofacitinib treatment on active MRI sacroiliitis in psoriatic arthritis patients. Rheumatology Science and Practice 59:2, pages 134-140.
Crossref
Hannah A. Blair. (2021) Secukinumab: A Review in Psoriatic Arthritis. Drugs 81:4, pages 483-494.
Crossref
Roberta Ramonda, Mariagrazia Lorenzin, Antonio Carriero, Maria Sole Chimenti, Raffaele Scarpa, Antonio Marchesoni, Ennio Lubrano, Carlo Salvarani, Alberto Cauli, Angelo Semeraro, Leonardo Santo, Augusta Ortolan, Andrea Doria, Elena Fracassi, Giulia Virelli, Marco Masia, Rosalinda Fanizzi, Elisa Visalli, Giorgio Amato, Antonio Carletto & Rosario Foti. (2021) Effectiveness and safety of secukinumab in 608 patients with psoriatic arthritis in real life: a 24-month prospective, multicentre study. RMD Open 7:1, pages e001519.
Crossref
Oh Chan Kwon, Jung Hwan Park & Min-Chan Park. (2021) Factors affecting drug survival of an alternative TNF inhibitor and secukinumab in patients with ankylosing spondylitis switching from the first TNF inhibitor. Therapeutic Advances in Musculoskeletal Disease 13, pages 1759720X2110090.
Crossref
Chia-Ling Yu, Chung-Han Yang & Ching-Chi Chi. (2020) Drug Survival of Biologics in Treating Ankylosing Spondylitis: A Systematic Review and Meta-analysis of Real-World Evidence. BioDrugs 34:5, pages 669-679.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.